⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

Hepatitis C is curable — for almost everyone. Modern pills called direct-acting antivirals (DAAs) cure more than 95% of people. A typical course is one to three pills once a day for 8 to 12 weeks, usually with few or no side effects. This is nothing like the old interferon shots that took up to a year, made people very ill, and cured fewer than half.
“Cure” has a precise meaning: SVR12. If your blood has no detectable hepatitis C virus 12 weeks after you finish treatment, that is a sustained virologic response (SVR12) — considered a permanent cure. The virus does not come back on its own.
Everyone should be tested at least once. The CDC and the U.S. Preventive Services Task Force recommend a one-time hepatitis C test for all adults, and a test during every pregnancy. Most people have no symptoms for decades, so testing — not symptoms — is how the infection is found.
You usually don’t need genotype testing anymore. The two main regimens — sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) — are “pangenotypic,” meaning they work against all six major types of the virus. One regimen fits almost everyone.
Many people can be cured by their regular doctor. Simplified treatment lets primary care clinicians — and in some clinics pharmacists or nurses — treat people who don’t have cirrhosis, with very little lab monitoring. New rapid tests can confirm active infection in about an hour, so some clinics now “test and treat” in a single visit.
Active drug or alcohol use is not a reason to be denied treatment. Guidelines are explicit: you should be treated regardless of how much liver scarring you have, whether you drink, and whether you inject drugs. Sobriety is not required. People who inject drugs are excellent candidates for cure.
Two safety checks happen before you start. Your clinician should test you for hepatitis B (the virus can “wake up” during treatment — an FDA warning) and review every medicine and supplement you take for interactions.
One heart-rhythm drug is dangerous with these pills. Amiodarone combined with sofosbuvir can cause a dangerously slow heart rate. Tell your clinician if you take it. Also mention acid reducers (like omeprazole), statins, seizure medicines, HIV medicines, and St. John’s wort.
If you already have cirrhosis, two things change. First, people with advanced (decompensated) cirrhosis must avoid the “previr” drugs and be treated at a liver center. Second, even after you’re cured, you still need an ultrasound of your liver every 6 months to screen for liver cancer, because the risk drops but does not disappear.
Cure is not immunity. Being cured does not protect you from catching hepatitis C again. If you have ongoing exposure (for example, sharing injection equipment), prevention and periodic re-testing matter. There is no hepatitis C vaccine yet.

▼ Collapse

Overview: What Hepatitis C Is — and Why the Story Has Changed

Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). It spreads when blood from an infected person enters the bloodstream of another person — most commonly today through shared needles or other injection equipment, but historically through blood transfusions (before 1992 in the U.S.), unsterile medical or dental procedures, tattooing with unsterile equipment, and, less often, from a parent to a baby during birth. It is not spread by casual contact, sharing food, hugging, or coughing.

The headline: Hepatitis C has gone from a chronic, often progressive disease treated with a year of toxic injections to a curable infection treated with 8–12 weeks of well-tolerated pills. For nearly everyone living with hepatitis C today, cure is not just possible — it is expected.

Acute vs. chronic — and why most people don’t know they have it

For the first six months after infection (“acute” hepatitis C), most people feel nothing at all. A minority — roughly a quarter to a third — clear the virus on their own without any treatment. The rest develop chronic hepatitis C, which can quietly inflame and scar the liver over years to decades. Because symptoms are usually absent until the liver is badly damaged, hepatitis C has been called a “silent” infection. That is exactly why one-time testing of all adults matters so much: it finds the infection before the damage is done.

What happens if it’s left untreated

Over many years, ongoing inflammation can cause scarring (fibrosis) that progresses through stages, sometimes ending in cirrhosis (stage F4 — heavy, permanent scarring). A liver with cirrhosis can still work for a long time (“compensated” cirrhosis), but it can also begin to fail (“decompensated” cirrhosis), and it carries an ongoing risk of liver cancer (hepatocellular carcinoma). Untreated hepatitis C is a leading cause of liver transplantation. The good news is the mirror image: finding and curing the infection before cirrhosis develops removes nearly all of this future risk.

Think of liver scarring as a one-way street that you can stop at any time — but the earlier you stop, the more the liver can recover. If you are cured before significant scarring forms, your liver-related risk afterward is close to that of someone who never had hepatitis C, and you generally will not need ongoing liver-cancer screening. If you are cured only after cirrhosis has formed, the cure still dramatically lowers your risk of liver failure, cancer, transplant, and death — but a reduced risk of liver cancer remains, so screening continues. The lesson is simple: get tested, and if positive, get treated — the sooner the better.

HCV comes in six major types (genotypes 1 through 6). Genotype 1 is most common in the U.S. and Europe; genotype 3 is common in South Asia; genotype 4 dominates Egypt and the Middle East; genotype 6 is seen in Southeast Asia and southern China. In the past, your genotype decided your treatment. Today’s pangenotypic regimens work across all of them, so for most people genotype no longer needs to be tested before starting. It may still be checked in special situations (for example, after a previous treatment didn’t work).

How this guide is organized

This guide follows the journey most people take: Screening & Diagnosis (finding out), Treatment & Cure (the pills and how they’re prescribed), Cirrhosis & Advanced Liver Disease (what changes if the liver is already scarred), After Cure & Preventing Reinfection (staying well), and Support & Resources (where to get help, including in Utah). Each section has a Questions to Ask Your Doctor list and notes for caregivers.

A note for caregivers (you’ll find more in each section): Your most valuable roles are simple and powerful — helping your person take a once-daily pill consistently for a couple of months, helping them navigate insurance approval, and treating them without judgment or stigma. Hepatitis C carries a lot of unfair shame; your steadiness matters.

Have I been tested for hepatitis C? If not, can we do it today?
If my test is positive, does that mean I have an active infection right now?
How much — if any — scarring does my liver have, and how will you measure it without a biopsy?
Am I a candidate to be treated here in your office, or do I need a specialist?
How soon can I start treatment?

This guide is for education and does not replace advice from your own clinician. Hepatitis C care is evolving; always confirm specifics with your treating team.

Stage 1: Screening & Diagnosis

Diagnosing hepatitis C is a short, logical sequence. Understanding it helps you ask the right questions and avoid getting “lost” between tests.

Get tested at least once, even if you feel fine. All adults should be screened once in their lifetime, and pregnant people during every pregnancy. If you have ongoing risks (such as injecting drugs), you should be tested regularly — not just once.

Step 1: The antibody test

The first test is for HCV antibodies — proteins your immune system makes after exposure to the virus. A “non-reactive” (negative) result usually means you’ve never been infected (unless you were exposed very recently). A “reactive” (positive) result means you were infected at some point — but it does not tell you whether the virus is still in your body, because antibodies remain even after the virus is gone or cured.

Step 2: The RNA (viral load) test — the one that confirms active infection

A positive antibody test should automatically trigger an HCV RNA test (also called a viral load or PCR test). This looks for the virus itself. If RNA is detected, you have an active, current infection that can be cured. If RNA is not detected, you cleared the virus (on your own or from past treatment) and don’t need treatment now.

Same-visit “test and treat” is now real. A rapid point-of-care HCV RNA test (the Cepheid Xpert HCV test) can confirm active infection in about an hour from a finger-stick or blood sample. The 2025 AASLD/IDSA guidance includes a point-of-care “test-and-treat” algorithm so that, in suitable patients, a clinic can diagnose and start the cure in the same encounter — closing the gap where people often disappear between appointments. This is especially valuable in addiction-treatment programs, emergency departments, jails and prisons, and mobile/harm-reduction settings.

Step 3: Do you need a genotype test?

Usually not. Because the standard regimens are pangenotypic, most people start treatment without ever knowing their genotype. Your clinician may order it only if the result would change your plan — for example, after a prior treatment failure.

Step 4: Checking your liver — without a biopsy

Before (or as) you start, your clinician estimates how much scarring your liver has. The key question is simply: do you have cirrhosis or not? This is now done non-invasively — liver biopsy is rarely needed:

Blood-test scores (FIB-4 and APRI): simple calculations using routine labs (platelets, liver enzymes, age). A low score strongly suggests little or no scarring.
FibroScan (transient elastography): a painless bedside ultrasound-type probe that measures liver stiffness in about 10 minutes. Higher stiffness suggests more scarring.
MR elastography: an MRI-based version used in some centers for added accuracy.

Step 5: Baseline labs and other screens

Before starting DAAs, expect a small panel of tests: a complete blood count, liver and kidney function, and importantly screens for hepatitis B (because of a reactivation risk — see Treatment) and HIV. People who can become pregnant are usually offered a pregnancy test and counseling, especially if a ribavirin-containing regimen is being considered.

If you have a recent, new infection, your clinician may either monitor for a few months to see whether you clear it on your own, or simply treat it — the same all-oral regimens work for acute infection. Treating early also prevents passing the virus to others. Ask which approach makes sense for you. (After a needlestick or other occupational exposure, follow your workplace’s protocol; testing is done at set intervals.)

Push for the confirmatory RNA test. A common failure point is stopping after a positive antibody test. Make sure the RNA test happens — ideally the same day.
Help collect the medication list. Bring every prescription, over-the-counter product, vitamin, and herbal supplement (including the bottles) to the visit. This speeds the interaction check.
Watch for stigma — including self-stigma. A hepatitis C diagnosis can bring shame that has nothing to do with reality. Reassure your person that this is a treatable medical condition, full stop.
Ask about same-visit treatment. If your clinic offers point-of-care testing, treatment may be able to start immediately.

My antibody test was positive — what was my RNA (viral load) result? Do I have an active infection?
What is my genotype, and does it change anything for me?
Do I have cirrhosis? How are you measuring my liver scarring — FIB-4, FibroScan, or something else?
Have you checked me for hepatitis B and HIV before I start treatment?
Can I be diagnosed and start treatment in the same visit here?
Who will explain my results and the plan, and how do I reach them with questions?

Stage 2: Treatment & Cure

This is the heart of the good news. The medicines are simple, short, and highly effective, and most people tolerate them easily.

What “cured” means. The goal is SVR12 — no detectable virus 12 weeks after your last pill. Achieving SVR12 means the infection is gone and will not return on its own. More than 95% of people reach it with first-line therapy.

The two first-line pills (pangenotypic — work against all genotypes)

Sofosbuvir/velpatasvir (Epclusa) — one pill once daily, usually for 12 weeks. Can be taken with or without food. Cures all genotypes; in its main trial (ASTRAL-1) the cure rate was about 99%.
Glecaprevir/pibrentasvir (Mavyret) — three pills once daily with food, for just 8 weeks in treatment-naive people without cirrhosis (and for treatment-naive people with compensated cirrhosis, 8 weeks is also approved). Some other situations call for 12 or 16 weeks. Cure rates are consistently above 95%.

Both are taken at home. Which one you get often depends on your other medicines, your kidney function, whether you have cirrhosis, and what your insurance covers. They are equally good choices for most people; your clinician will match the regimen to you.

Simplified treatment — you may not need a specialist

If you are treatment-naive, not pregnant, have no prior DAA failure, and either have no cirrhosis or have compensated cirrhosis without complications, you likely qualify for the simplified treatment pathway. That means your primary care provider can prescribe one of the two regimens with minimal monitoring — often no on-treatment viral load checks at all — and confirm your cure with a single test 12 weeks after you finish.

You should be offered treatment regardless of fibrosis stage, alcohol use, or drug use. Guidelines have removed sobriety and “wait until you’re sicker’ requirements. If you are told you must be sober or must have advanced scarring to qualify, ask why — and consider a second opinion or a specialist clinic that follows current guidance.

If the first course doesn’t work: salvage therapy

For the small number of people whose first DAA course fails, sofosbuvir/velpatasvir/voxilaprevir (Vosevi) — one pill daily for 12 weeks — cures the large majority. The decision considers your prior regimen, any resistance, and whether you have cirrhosis, and is usually made with a specialist.

Ledipasvir/sofosbuvir (Harvoni) (for genotypes 1, 4, 5, 6) and elbasvir/grazoprevir (Zepatier) (for genotypes 1 and 4) are still effective and are used in some settings or for specific situations, but the pangenotypic regimens above are first-line for most people now.

Some people with decompensated cirrhosis or a previous treatment failure receive ribavirin alongside a DAA. Ribavirin can cause anemia (low red blood cells), so blood counts are watched. Critically, ribavirin can cause severe birth defects: it is strictly forbidden in pregnancy and requires reliable contraception in the patient and in female partners of male patients during and for a period after treatment.

Side effects — usually mild

Most people feel fine. The most common complaints with the pangenotypic regimens are mild headache, fatigue, and nausea. Serious side effects are uncommon. This is a world away from the interferon era. If something feels wrong, call your clinician rather than stopping on your own.

Drug interactions — the most important safety topic

Tell your clinician about every medicine and supplement before you start. Key interactions:

Amiodarone (a heart-rhythm drug) + sofosbuvir can cause a dangerously slow heartbeat. This combination is generally avoided.
Acid reducers — proton-pump inhibitors (omeprazole, esomeprazole, pantoprazole) and antacids — can lower the absorption of velpatasvir and ledipasvir. They may need to be reduced, timed differently, or paused. Don’t just stop a prescribed PPI without guidance.
Statins (cholesterol drugs) may need a lower dose or a temporary hold with some regimens.
Certain seizure medicines (carbamazepine, phenytoin), rifampin (an antibiotic), and St. John’s wort (an herbal product) can lower DAA levels and cause treatment to fail.
Some HIV medicines interact with DAAs and may need adjusting.

Your clinician can check any combination using the University of Liverpool HEP Drug Interaction Checker (hep-druginteractions.org).

Cost and patient-assistance — don’t let price stop you

List prices were historically high, but they have fallen, and most people pay far less through insurance, Medicaid, the VA, or manufacturer programs. Gilead (Epclusa) and AbbVie (Mavyret) both run patient-assistance and copay programs for eligible patients. Generic versions of some regimens also exist. If you hit a wall, ask the clinic’s pharmacist, social worker, or a patient navigator — getting these drugs approved is a routine part of their job.

What treatment is actually like, day to day

For most people, life barely changes during the 8–12 weeks. You take your pill (or pills) once a day, go about your normal routine, and feel essentially the same as before. You do not need to stop working, stay home, or avoid other people. There are no injections and no need to isolate. The virus is not spread by everyday contact, so you can hug your family, share meals, and live normally — just don’t share anything that might carry blood (razors, toothbrushes).

A missed dose is not a disaster. If you remember the same day, take it. If it’s nearly time for the next one, skip the missed dose and continue — don’t double up. Tell your clinic if you miss several days in a row.
Finish the whole course even when you feel completely fine (you may feel fine the whole time). Stopping early is the main avoidable reason treatment fails.
Mavyret must be taken with food; Epclusa can be taken with or without food. Pairing the pills with a regular meal makes both the timing and (for Mavyret) the food requirement automatic.
If you vomit shortly after a dose, ask your pharmacist whether to re-dose — don’t guess.
Don’t start any new medicine or supplement mid-treatment (including a new acid reducer, antibiotic, or herbal product) without checking it’s safe with your DAA.

What monitoring (if any) to expect

If you’re on the simplified pathway without cirrhosis, you may have no blood tests at all during treatment — just the one test 12 weeks after you finish to confirm cure (SVR12). Some people (for example, those on warfarin, those with diabetes, or those with cirrhosis) have a few checks along the way. Your clinician will tell you your specific schedule. The key appointment to protect is the SVR12 test — that’s the one that confirms you’re cured.

Liver-protective steps during and after treatment

Avoid alcohol (it adds injury and can blunt recovery).
Get vaccinated against hepatitis A and hepatitis B if you’re not already immune.
Work on weight and metabolic health to limit fatty-liver injury.
Review all medicines and herbal products for liver safety with your clinician or pharmacist.

Make the once-daily pill effortless. Tie it to an existing habit (morning coffee, brushing teeth), set a phone alarm, or use a weekly pill organizer. For Mavyret, remember it’s taken with food — pair it with a meal.
Help with the insurance maze. Prior authorization, pharmacy transfers, and assistance-program paperwork are the most common reasons treatment stalls. Offer to make calls or sit in on them.
Keep the full medicine list current. If a new prescription is added during treatment (antibiotic, acid reducer, statin), make sure the prescriber knows the person is on a DAA.
Encourage, don’t police. A missed dose now and then is not a catastrophe — just resume. Shame and pressure backfire. Steady, kind reminders win.
Mark the SVR12 date. Put the “12 weeks after the last pill” blood test on the calendar — that’s the test that confirms cure.

Which regimen is right for me — Epclusa or Mavyret — and for how long (8 vs 12 weeks)? Why that one?
Can my primary care provider treat me, or do I need a specialist?
What does SVR12 mean for me, and when exactly is the test that confirms my cure?
Have you reviewed all my medicines and supplements — including my acid reducer, statin, and any heart medicine like amiodarone?
What side effects should I expect, and when should I call you?
What will this cost me, and can you help me with patient-assistance or copay programs?
What happens if treatment doesn’t work the first time?
Do I need any monitoring during treatment, or just the cure test at the end?
What should I do if I miss a dose or accidentally skip a day?
If I’m prescribed a new medicine during treatment, who should I check with first?

Stage 3: Cirrhosis & Advanced Liver Disease

If your liver already has heavy scarring, you can still be cured — but a few things change about how you’re treated and what care continues afterward. This section is also written so caregivers can recognize the danger signs that require urgent help.

Compensated vs. decompensated cirrhosis

Compensated cirrhosis means the liver is scarred but still doing its jobs; many people feel well and have normal daily life. Decompensated cirrhosis means the liver is starting to fail, producing complications such as fluid buildup in the belly (ascites), confusion (hepatic encephalopathy), or internal bleeding from swollen veins (variceal bleeding). The distinction is crucial because it changes which medicines are safe.

Safety-critical: If you have decompensated cirrhosis (doctors may call this Child-Pugh B or C), you must not take the “previr” protease-inhibitor drugs — glecaprevir (in Mavyret), voxilaprevir (in Vosevi), or grazoprevir (in Zepatier) — because they can be harmful to a failing liver. Instead you’ll be treated with a sofosbuvir-based regimen (such as sofosbuvir/velpatasvir), often with ribavirin added, ideally at a liver center.

Treating cirrhosis: still very curable

People with compensated cirrhosis are cured at rates similar to everyone else and are eligible for the simplified pathway (with a cirrhosis-appropriate plan). People with decompensated cirrhosis are also frequently cured, with the protease-inhibitor-free regimens above; their care is coordinated by a hepatologist and often a transplant team.

Compensated cirrhosis often comes with few or no symptoms. Many people work, travel, and live normally for years; the scarring is there, but the liver is still keeping up. The main changes to your care are regular monitoring (a liver ultrasound every 6 months and, often, a one-time look for swollen veins in the esophagus).

Decompensated cirrhosis means the liver has started to fall behind, producing visible problems — fluid in the belly (ascites), confusion (encephalopathy), yellowing (jaundice), or bleeding from swollen veins. This stage needs specialist (hepatologist) care, a carefully chosen medication regimen, and usually a conversation about transplant. Importantly, curing the virus at this stage can sometimes improve liver function — occasionally enough that a transplant is no longer needed.

Liver ultrasound every 6 months (sometimes with a blood test called AFP) to catch liver cancer early.
An upper endoscopy (a camera down the throat) at some point to check for swollen veins (varices) that could bleed; if found, there are medicines or procedures to lower the risk.
Periodic blood tests (liver function, blood counts, kidney function, clotting) to track how the liver is doing.
Your team may calculate a score (such as MELD) that summarizes liver function and helps decide timing of treatment and, if needed, transplant.

Liver transplant — when it’s needed

For end-stage liver disease or for liver cancer that can’t be controlled other ways, a liver transplant can be life-saving. Hepatitis C is no longer a barrier: it can be cured before or after transplant. Curing the virus sometimes improves liver function enough that transplant is no longer needed; in other cases it’s cured after transplant. Transplant centers can also now safely use organs from hepatitis-C-positive donors for recipients (curing them afterward), which has expanded the donor pool and shortened waits.

If transplant is on the table, expect an evaluation phase: many appointments and tests to confirm you’re a candidate and to place you on the waiting list. Waiting times vary. Accepting an organ from a hepatitis-C-positive donor (and being cured afterward) can shorten your wait — your team will explain this option and its now-very-low risks. After transplant, the most important job is taking anti-rejection medicines exactly as prescribed, every day, for life, and keeping every follow-up. A caregiver who helps track medicines and appointments makes a real difference here.

Liver-cancer screening — before and after cure

If you have cirrhosis or advanced scarring, you need an ultrasound of your liver every 6 months (sometimes with a blood test called AFP) to catch liver cancer early — and this continues even after you’re cured. Cure lowers cancer risk substantially but does not erase it. People cured before developing significant scarring generally do not need ongoing screening.

Red flags — call 911 or get emergency care:

Vomiting blood or passing black, tarry stools (possible variceal bleeding).
New or worsening confusion, drowsiness, slurred speech, or disorientation (possible hepatic encephalopathy).
Rapid abdominal swelling, severe belly pain, or fever (possible infected ascites).
Yellowing of the eyes/skin that is rapidly worsening, or sudden severe weakness.

Learn the encephalopathy signs. Subtle confusion, reversed sleep–wake cycle, a flapping hand tremor, or personality change can be early. Know the medicines (such as lactulose) prescribed to prevent it, and help with the dosing schedule.
Track the belly. Sudden swelling, weight gain, or abdominal pain with fever warrants a same-day call.
Keep the 6-month liver ultrasound on the calendar — before and after cure if cirrhosis is present. This is one of the most important things you can do.
Support the transplant evaluation. If transplant is on the table, there are many appointments and a lot of paperwork; a second set of ears and hands is invaluable.
Caring for someone before or after a transplant means medication adherence (anti-rejection drugs are non-negotiable), infection vigilance, and keeping every follow-up. Ask the transplant team for their written caregiver instructions.

Do I have cirrhosis, and is it compensated or decompensated?
Given my liver, which regimen is safe for me — and which drugs must I avoid?
Should I be treated at a liver/transplant center?
Do I need to be evaluated for a liver transplant now or later?
How often do I need liver-cancer screening, and will that continue after I’m cured?
Do I need to be checked for swollen veins (varices) in my esophagus?
What symptoms mean I should call you, and which mean I should call 911?
If transplant might be needed, what does the evaluation involve, and would accepting a hepatitis-C-positive donor organ shorten my wait?
What is my MELD (or other liver) score, and how does it affect my treatment timing?

Stage 4: After Cure & Preventing Reinfection

Reaching SVR12 is a real milestone — the virus is gone. This section covers what cure does (and doesn’t) protect you from, and how to stay well.

Cure changes your future. Clearing the virus halts ongoing liver damage, lets some scarring partially heal over time, and sharply lowers the risk of liver failure, liver cancer, transplant, and death. People treated before cirrhosis essentially return to a normal liver-risk life.

Cure is not immunity — reinfection is possible

Being cured does not make you immune. If you’re exposed to infected blood again — most commonly by sharing injection or drug-preparation equipment — you can get hepatitis C again. This is not a moral failing or a sign the cure “didn’t work”; it’s a new, separate infection that can be cured again. The goal is to lower the chance of it happening.

How to avoid getting hepatitis C again

Never share injection equipment — needles, syringes, cookers, cotton, water, or ties. Use new sterile supplies every time (syringe service programs provide them free).
Consider medication for opioid use disorder (such as buprenorphine or methadone) if relevant — it dramatically reduces injection-related risk and is fully compatible with HCV cure.
Don’t share items that may carry blood — razors, toothbrushes, glucose-monitoring lancets.
Choose licensed, sterile tattoo and piercing providers.
If you have ongoing exposure, get re-tested periodically with an RNA (viral load) test — antibodies stay positive after cure, so only the RNA test detects a new infection.

Continued liver-cancer screening (only if you had cirrhosis/advanced scarring)

If you had cirrhosis or advanced fibrosis before cure, keep up the every-6-month liver ultrasound (with or without AFP). If you were cured before significant scarring, ongoing screening generally isn’t needed — ask your clinician which group you’re in.

This depends on whether you have ongoing exposure:

No ongoing risk (no injecting, no new exposures): you generally don’t need routine hepatitis C re-testing after cure.
Ongoing risk (for example, you still inject sometimes, or you’re in a setting with exposure): you should have an HCV RNA (viral load) test at least once a year, and sooner if you have a new exposure or a clinician notices a change in your liver blood tests.
Always the RNA test, never the antibody test, to check for a new infection — your antibody test will stay positive for life and can’t tell old from new.

If a new infection is found, it’s simply treated again with the same kind of pills. Getting reinfected is a medical event, not a personal failure.

Reaching SVR12 means the virus is gone for good (it doesn’t come back on its own). Over the following months and years, ongoing liver damage stops, and some scarring can partially heal. Your risk of liver failure, the need for a transplant, and death from liver disease all drop substantially. If you were cured before serious scarring, your liver-related outlook is close to that of someone who never had hepatitis C. If you already had cirrhosis, you’re much better off cured — but you keep the 6-month liver-cancer screening because some risk remains. Many problems hepatitis C can cause outside the liver (certain skin, kidney, nerve, and blood-vessel conditions) often improve after cure, too.

Other long-term wellness

Stay vaccinated against hepatitis A and B if you’re not immune.
Limit or avoid alcohol; manage weight, blood sugar, and cholesterol to protect the liver from fatty-liver injury.
Some problems caused by chronic HCV outside the liver — such as certain skin, kidney, or nerve conditions, and a type of blood-vessel inflammation called cryoglobulinemia — often improve after cure.
Tell future clinicians you were treated for and cured of hepatitis C; your antibody test will remain positive for life.

There is no hepatitis C vaccine yet. Because the virus mutates quickly, a preventive vaccine has been hard to make and none is approved. Research continues. For now, prevention relies on safe equipment, treatment-as-prevention (curing people reduces spread), and harm reduction.

Celebrate the SVR12. It’s a genuine win — acknowledge it.
Support harm reduction without judgment. If your loved one injects drugs, connecting them to a syringe service program and to addiction treatment is one of the most protective things you can do. Stigma drives people away from care; acceptance keeps them in it.
Keep the screening rhythm if cirrhosis is present — the 6-month ultrasound matters for life.
Normalize periodic re-testing for anyone with ongoing exposure. Reinfection is a medical event, not a character verdict.

Am I officially cured (did I reach SVR12)?
Do I still need liver-cancer screening — and for how long?
Given my situation, how do I avoid getting hepatitis C again, and how often should I be re-tested?
Am I immune to hepatitis A and B, or do I need those vaccines?
Will my antibody test always be positive now? What should I tell future doctors?
Given my situation, exactly how often should I get an RNA (viral load) test to check for a new infection?
If I have ongoing drug use, can you connect me with harm-reduction and treatment services?

Support & Resources

This section pulls together caregiver guidance, where to get care (with a focus on Utah and the Mountain West), how to find clinical trials, what treatments have not worked, how access differs around the world, a glossary, and the key sources behind this guide.

For caregivers — your toolkit

The four things that help most: (1) help with daily pill adherence over the 8–12 weeks; (2) help navigating insurance prior authorization and patient-assistance programs; (3) treating your person without stigma; and (4) keeping the right follow-up — the SVR12 cure test for everyone, and the 6-month liver-cancer ultrasound for anyone with cirrhosis.

Adherence: alarms, pill organizers, habit-stacking; remember Mavyret is taken with food.
Insurance/access: lean on the clinic pharmacist, social worker, or patient navigator; use Gilead and AbbVie assistance programs.
Stigma: language matters — “a person who injects drugs,” not “an addict”; “a person with hepatitis C,” not “infected.”
Advanced disease: learn encephalopathy and bleeding red flags (see Cirrhosis section); keep emergency numbers handy.
Harm reduction: support syringe services and addiction treatment without judgment.
Transplant: request the team’s written caregiver instructions; anti-rejection medicines are non-negotiable.

Specialty Center Directory

Phone numbers and programs change; please verify before relying on them. Listing here is informational, not an endorsement.

Mountain West & Utah

University of Utah Health — Hepatology / Liver Center (Salt Lake City). Evaluation and DAA treatment, non-invasive fibrosis staging (FibroScan), cirrhosis and portal-hypertension care, liver-cancer surveillance, and liver transplant evaluation (the regional transplant center, including protocols using hepatitis-C-positive donor organs). Main line: 801-581-2121; transplant program: 801-581-2879.
Intermountain Health — Gastroenterology/Hepatology (Wasatch Front & southern Utah). Hepatitis C testing and treatment, including primary-care-based simplified treatment. Find a provider via Intermountain’s main scheduling: 801-442-3000.
Utah Department of Health and Human Services — Viral Hepatitis Program. Testing resources, linkage-to-care, and information on Utah’s hepatitis C elimination efforts. General DHHS line: 801-538-6191.
Utah Naloxone & local syringe service / harm-reduction programs. Sterile supplies, naloxone, linkage to addiction treatment (opioid agonist therapy), and judgment-free hepatitis C testing and treatment. Utah Naloxone: utahnaloxone.org.
VA Salt Lake City Health Care System (George E. Wahlen VA Medical Center). Veterans can be screened and treated through VA hepatology and primary care — the VA has been a national leader in HCV elimination. Main line: 801-582-1565.

U.S. National Centers of Excellence

Johns Hopkins (Baltimore) — viral hepatitis, HIV/HCV coinfection, and HCV-positive-donor transplant research.
University of Pennsylvania (Philadelphia) — hepatology and the THINKER HCV-positive-donor transplant program.
UW Medicine / Hepatitis C Online (Seattle) — clinical care plus the widely used free education resource at hepatitisc.uw.edu.
Mayo Clinic (Rochester, Phoenix, Jacksonville) and Cleveland Clinic — comprehensive hepatology and transplant.
UCSF (San Francisco) — hepatology, PWID-focused models, and elimination research.

Veterans

The VA screens and treats hepatitis C system-wide and has cured a very large number of veterans. Ask your VA primary care team or hepatology clinic. Hepatitis C related to certain service exposures may be relevant to VA benefits — ask a Veterans Service Officer about service connection.

Canada

Toronto Centre for Liver Disease (University Health Network), University of Calgary Liver Unit, and CHUM (Montréal) are major centers. DAAs are covered through provincial and territorial drug plans (coverage details vary by province); the CADTH process informs reimbursement.

International

Egypt — National Committee for the Control of Viral Hepatitis (the “100 Million Healthy Lives” program) for screen-and-treat at national scale.
Georgia (country) — national HCV elimination program (the world’s first, launched 2015).
Specialist liver centers affiliated with EASL across Europe, and national hepatitis programs in Australia (an elimination leader) and elsewhere.

Clinical Trials — how to find them

The DAA cure is so effective that most current research focuses on delivering the cure (test-and-treat models, treatment in pregnancy, expanding 8-week therapy, organs from HCV-positive donors) and on a future vaccine, rather than on new pills for typical infection.

ClinicalTrials.gov — search “hepatitis C” and filter by “recruiting” and your location.
Examples of real, completed landmark studies you may see referenced: the registration trials ASTRAL-1 (NCT02201940) and ENDURANCE-1 (NCT02604017); the salvage trials POLARIS-1/4 (NCT02607735 / NCT02639247); the minimal-monitoring MINMON study (ACTG A5360); the pediatric DORA study (NCT03067129); and the HCV-positive-donor kidney transplant trial THINKER (NCT02743897). (See the clinical companion guide for a full audited list.)
Ask the University of Utah Hepatology program or the VA whether any active study fits your situation.

Failed / De-adopted Therapies — what does NOT cure hepatitis C

You will encounter claims online. Here is an honest summary:

Interferon and ribavirin alone (the old standard): not de-adopted because it was useless — it cured some people — but it is now obsolete for almost everyone because it took up to a year, caused severe side effects, and cured fewer than half. Interferon is no longer recommended.
“Liver detoxes,” cleanses, and most supplements: do not cure hepatitis C. Milk thistle (silymarin), in particular, has been studied and does not clear the virus or reliably change liver outcomes — it is not a treatment.
High-dose vitamins, colloidal silver, ozone, and similar: no evidence of cure; some can harm the liver.
Stopping DAAs early because you “feel cured”: finishing the full course is what achieves cure; stopping early risks failure and resistance.
Herbal products can be dangerous, not just useless. Some herbal and “immune-boosting” supplements interact with DAAs (St. John’s wort lowers drug levels) or can themselves injure the liver. Always review supplements with your clinician. None is a substitute for standard care.

Bottom line: the only proven cure for hepatitis C is a course of direct-acting antiviral pills. If a product promises to “cure” or “flush” hepatitis C without DAAs, it is not telling the truth.

International Access & Regulatory Landscape (plain-language)

Same drugs, very different prices. Generic sofosbuvir-based regimens (made under licensing in India, Egypt, and elsewhere) have brought cure within reach in many lower-income countries, while wealthy countries historically paid high list prices that have since fallen.
Approvals are broadly aligned. Epclusa and Mavyret are approved by the U.S. FDA, the European EMA, Health Canada, the UK (with NICE guidance), Japan’s PMDA, and China’s NMPA, among others. Europe’s EASL guidance mirrors the U.S. pangenotypic, treat-everyone approach.
Some places have extra options. China has approved several home-grown DAAs not sold in the West; generic sofosbuvir/daclatasvir is widely used across Asia, Africa, and Latin America.
Restrictions are easing but not gone. Some health systems and insurers once limited treatment to people with advanced scarring or required sobriety; most such rules have been removed and are discouraged by guidelines, but a few remain — worth asking about where you live.
Whole countries are eliminating it. The World Health Organization aims to eliminate hepatitis C as a public-health threat by 2030; Egypt and Georgia have shown national elimination is achievable.

HCV: hepatitis C virus.
Acute / chronic: the first 6 months after infection / infection lasting beyond 6 months.
Antibody test: shows past exposure; stays positive after cure.
RNA / viral load test: shows whether the virus is active now; the test used to confirm infection and, later, reinfection.
Genotype: the “family” of the virus (1–6); rarely needed now.
DAA: direct-acting antiviral — the modern pills that cure HCV.
Pangenotypic: works against all six genotypes.
SVR12: sustained virologic response — no virus 12 weeks after treatment; the definition of cure.
Fibrosis (F0–F4): liver scarring, from none (F0) to cirrhosis (F4).
Cirrhosis: heavy, permanent scarring; “compensated” (still working) or “decompensated” (failing).
FibroScan: painless scan that measures liver stiffness to estimate scarring.
HCC: hepatocellular carcinoma — the main type of liver cancer.
Ascites: fluid buildup in the abdomen.
Hepatic encephalopathy: confusion/brain effects from a failing liver.
Varices: swollen veins (often in the esophagus) that can bleed.
Ribavirin: an older add-on medicine; causes anemia; unsafe in pregnancy.
Protease inhibitor / “previr” drugs: glecaprevir, voxilaprevir, grazoprevir — avoided in decompensated cirrhosis.
Harm reduction: practical steps (sterile supplies, naloxone, addiction treatment) that reduce harm without requiring abstinence.

AASLD/IDSA HCV Guidance — living guidance at hcvguidelines.org, including the 2025 Point-of-Care Test-and-Treat Algorithm and the Simplified Treatment Algorithm.
USPSTF (2020) and CDC (2020) — universal one-time HCV screening for adults and screening in every pregnancy.
EASL Recommendations on Treatment of Hepatitis C — European guidance, aligned with the pangenotypic, treat-everyone approach.
WHO (2022) Guidelines for the care and treatment of persons with chronic HCV and the WHO 2030 elimination strategy.
FDA labels for Epclusa (sofosbuvir/velpatasvir), Mavyret (glecaprevir/pibrentasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Harvoni, and Zepatier — including the HBV-reactivation boxed warning and the amiodarone–sofosbuvir warning.
Landmark trials — ASTRAL-1/2/3/4/5, ENDURANCE-1/3, EXPEDITION-2/4/8, SURVEYOR-2, POLARIS-1/4, ION-1/2/3, DORA, and THINKER (see the clinical companion guide for full identifiers and an NCT audit).
University of Liverpool HEP Drug Interaction Checker — hep-druginteractions.org.
Hepatitis C Online (UW) — hepatitisc.uw.edu, a free, regularly updated clinical education resource.

Final word. Hepatitis C is one of modern medicine’s great success stories. If you have it, you can almost certainly be cured — usually with a short course of well-tolerated pills, often through your regular doctor, sometimes in a single visit. Get tested. If positive, get treated. And if you have cirrhosis, keep up the 6-month liver screening even after you’re cured.

This guide is educational and does not substitute for individualized medical advice. Treatment decisions depend on your specific situation and should be made with a qualified clinician. Evidence and access continue to evolve; verify specifics with your care team and current guidelines.